XML 58 R48.htm IDEA: XBRL DOCUMENT
v3.23.2

Research, Consulting and Supply Agreements (Details Narrative) |  | 1 Months Ended | 3 Months Ended | 6 Months Ended | 12 Months Ended |
--- | --- | --- | --- | --- | --- | ---
Jun. 13, 2022 USD ($) | Aug. 14, 2023 USD ($) | Apr. 30, 2022 USD ($) | Dec. 31, 2021 USD ($) | Jun. 30, 2023 USD ($) | Jun. 30, 2022 USD ($) | Mar. 31, 2022 USD ($) | Jun. 30, 2023 USD ($) | Jun. 30, 2022 USD ($) | Dec. 31, 2022 USD ($) | Dec. 31, 2021 USD ($) | Dec. 31, 2017 Integer | Mar. 31, 2023 USD ($)
Research and development expense |  |  |  |  | $ 2,953,000 | $ 2,475,000 |  | $ 5,005,000 | $ 3,511,000 |  |  |  |
Amarex Clinical Research LLC [Member] |  |  |  |  |  |  |  |  |  |  |  |  |
Research and development expense | $ 6,400,000 |  |  |  |  |  |  | 538,000 |  |  |  |  |
Research and development expense |  |  | $ 8,200,000 |  |  |  |  |  |  |  |  |  |
Development cost | 125,470 |  | $ 1,000,000.0 |  |  |  |  |  |  |  |  |  |
Estimated lives |  |  | 4 years 7 months 6 days |  |  |  |  |  |  |  |  |  |
Invigilators cost | $ 4,400,000 |  |  |  |  |  |  |  |  |  |  |  |
Amarex Clinical Research LLC [Member] | Pancreatic Cancer [Member] |  |  |  |  |  |  |  |  |  |  |  |  |
Research and development expense |  |  |  |  |  |  |  | 233,400 |  |  |  |  |
Amarex Clinical Research LLC [Member] | Post COVID [Member] |  |  |  |  |  |  |  |  |  |  |  |  |
Research and development expense |  |  |  |  |  |  |  | 304,600 |  |  |  |  |
HVIVO Services Limited [Member] | Reservation and Start Up Agreement [Member] |  |  |  |  |  |  |  |  |  |  |  |  |
Research and development expense |  |  |  | $ 2,340,000 |  |  |  |  |  |  |  |  |
Cancellation fees |  |  |  |  |  |  | $ 60,000 |  |  |  |  |  |
Impatients NV [Member] | Research Consulting and Supply Agreements [Member] |  |  |  |  |  |  |  |  |  |  |  |  |
Research and development expense |  |  |  |  |  |  |  | 18,000 |  |  |  |  |
Jubilant Hollister Stier [Member] |  |  |  |  |  |  |  |  |  |  |  |  |
Research and development expense | Integer |  |  |  |  |  |  |  |  |  |  |  | 16,000 |
Research and development expense |  |  |  |  |  |  |  |  |  |  |  |  | $ 1,432,257
Jubilant Hollister Stier [Member] | Research Consulting and Supply Agreements [Member] |  |  |  |  |  |  |  |  |  |  |  |  |
Research and development expense |  |  |  |  |  |  |  | 0 |  |  |  |  |
Jubilant Hollister Stier [Member] | Research Consulting and Supply Agreements [Member] | Subsequent Event [Member] |  |  |  |  |  |  |  |  |  |  |  |  |
Research and development expense |  | $ 1,432,257 |  |  |  |  |  |  |  |  |  |  |
Pharmaceutics International, Inc [Member] |  |  |  |  |  |  |  |  |  |  |  |  |
Research and development expense |  |  |  |  |  |  |  |  |  | $ 278,000 |  |  |
Pharmaceutics International, Inc [Member] | Research Consulting and Supply Agreements [Member] |  |  |  |  |  |  |  |  |  |  |  |  |
Research and development expense |  |  |  |  |  |  |  | 55,400 |  |  |  |  |
Polysciences Inc [Member] |  |  |  |  |  |  |  |  |  |  |  |  |
Research and consulting |  |  |  |  |  |  |  |  |  |  | $ 250,000 |  |
Polysciences Inc [Member] | Research Consulting and Supply Agreements [Member] |  |  |  |  |  |  |  |  |  |  |  |  |
Research and development expense |  |  |  |  |  |  |  | 0 |  |  |  |  |
Yamasa Corporation [Member] |  |  |  |  |  |  |  |  |  |  |  |  |
Research and development expense |  |  |  |  |  |  |  |  |  |  |  |  | $ 327,730
Yamasa Corporation [Member] | Research Consulting and Supply Agreements [Member] |  |  |  |  |  |  |  |  |  |  |  |  |
Research and development expense |  |  |  |  |  |  |  | 0 |  |  |  |  |
Pharma Solutions [Member] | Master Service Agreement and Quality Agreement [Member] |  |  |  |  |  |  |  |  |  |  |  |  |
Research and development expense |  |  |  |  |  |  |  | $ 357,000 |  |  |  |  |

X
- Definition Cancellation fees. + References No definition available. + Details
Name: | AIM_CancellationFees
Namespace Prefix: | AIM_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Payments for research and consulting. + References No definition available. + Details
Name: | AIM_PaymentsForResearchAndConsulting
Namespace Prefix: | AIM_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Research and development expense cost estimated lives. + References No definition available. + Details
Name: | AIM_ResearchAndDevelopmentExpenseCostEstimatedLives
Namespace Prefix: | AIM_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Units manufactured. + References No definition available. + Details
Name: | AIM_UnitsManufactured
Namespace Prefix: | AIM_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Cost of maintenance incurred and directly related to good produced and service rendered. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(b)(2)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2 + Details
Name: | us-gaap_CostMaintenance
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The capitalized costs incurred during the period (excluded from amortization) to obtain access to proved reserves and to provide facilities for extracting, treating, gathering and storing the oil and gas. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 932 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-10(c)(7)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479664/932-10-S99-1 + Details
Name: | us-gaap_DevelopmentCosts
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The aggregate carrying amount as of the balance sheet date of items held by the entity which are partially completed at the time of measurement and unprocessed items that will go through the production process and become part of the final product. Includes supplies used directly or indirectly in the manufacturing or production process. This element may be used when the reporting entity combines work in process and raw materials into an aggregate amount. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details
Name: | us-gaap_InventoryWorkInProcessAndRawMaterials
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 912 -SubTopic 730 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 985 -SubTopic 20 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1 + Details
Name: | us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1 + Details
Name: | us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Details
Name: | dei_LegalEntityAxis=AIM_AmarexClinicalResearchLLCMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=AIM_PancreaticCancerMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=AIM_PostCOVIDMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=AIM_HVIVOServicesLimitedMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=AIM_ReservationAndStartUpAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=AIM_ImpatientsNVMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=AIM_ResearchConsultingAndSupplyAgreementsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=AIM_JubilantHollisterStierMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=AIM_PharmaceuticsInternationalIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=AIM_PolysciencesIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=AIM_YamasaCorporationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=AIM_PharmaSolutionsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=AIM_MasterServiceAgreementAndQualityAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |